# Phase I Study of the Combination of Anlotinib With Pemetrexed or Docetaxel

> **NCT03566576** · NA · UNKNOWN · sponsor: **Fujian Cancer Hospital** · enrollment: 18 (estimated)

## Conditions studied

- Non-squamous Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Anlotinib
- **DRUG:** Pemetrexed
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT03566576
- **Lead sponsor:** Fujian Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-07-01
- **Primary completion:** 2018-09-01
- **Final completion:** 2018-10-01
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2018-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03566576

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03566576, "Phase I Study of the Combination of Anlotinib With Pemetrexed or Docetaxel". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03566576. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*